Achilles tendinopathy is a clinical condition characterized by pain and tenderness in or around Achilles tendon, occurring frequently in active, as well as, inactive individuals [12]. Activity modification, stretching, anti-inflammatories, physiotherapy, and eccentric loading exercise are known as standard conservative treatment [3456]. In chronic refractory cases that exhibited no improvement after conservative treatment, surgical intervention has been performed [478].

Recently, extracorporeal shockwave therapy (ESWT) has emerged as an therapeutic alternative prior to considering surgical option [247891011]. Despite high evidence of efficacy of ESWT on chronic refractory Achilles tendinopathy [2], some cases still do not respond to ESWT for unknown reasons, causing subjects complain of residual symptoms. Therefore, it becomes important to know which patient is more amenable to ESWT. With regard to standard conservative treatment, Bakkegaard et al. [12] have reported that ultrasonography (US) findings influence the outcome of chronic Achilles tendinopathy. However, no study has investigated the factors associated with the therapeutic outcome of ESWT in patients with chronic refractory Achilles tendinopathy. Therefore, the aim of our study was to investigate the factors influencing outcome of ESWT for chronic refractory Achilles tendinopathy.

A total of 45 feet (33 patients) who met our eligibility criteria were included. Ninety-six percent of them (43 feet, 31 patients) were available for long-term follow-up telephone interview (mean 26 weeks after ESWT). Range of long-term follow-up duration was as follows: 6–12 months in 15 feet; 12–24 months in 6 feet; 24–36 months in 5 feet; and 36–62 months in 17 feet. A significant decrease in subjective pain was noted in 43 feet at immediate and long-term follow-up, respectively (p<0.05) (Fig.2). The success rate of ESWT was 71.1% at immediate and 90.3% at long-term follow-up. Adverse reactions of the treatment such as bruise or swelling were not found in the present study. Table 2 shows basic characteristics of subjects according to immediate treatment outcome of ESWT. The univariate logistic regression analysis identified that the following factors were associated with immediate treatment success: absence of retrocalcaneal enthesophyte on X-ray; shorter mean duration of ‘post-treatment soreness’, and shorter duration of ‘post-treatment soreness after first ESWT’ (Table 3). However, other factors (age, sex, symptom duration, thickness of Achilles tendon, baseline NRS, baseline RMS, additional supervised exercise, previous steroid injection history, and DM) were not significantly associated with immediate treatment outcome (Table 3). Among US parameters, presence of pretreatment abnormal echogenicity of Achilles tendon was significantly associated with immediate treatment success (Table 3).

In terms of long-term treatment outcome, duration of ‘post-treatment soreness after first ESWT’ was found to be the only prognostic factor (odds ratio, 0.32; 95% confidence interval, 0.10–0.99). In other words, shorter duration of ‘post-treatment soreness after first ESWT’ turned out to be associated with long-term treatment success. In addition, immediate treatment success was significantly associated with long-term treatment success as revealed by Fisher exact test (p<0.05).

In our study, absence of retrocalcaneal enthesophyte on X-ray was regarded as a positive factor associated with immediate treatment success of ESWT for chronic refractory Achilles tendinopathy. This finding can be explained based on the results of previous studies. Retrocalcaneal enthesophytes may be an adaptive response to increased traction in the Achilles tendon [2021]. Increased mechanical loading triggers osteoblastic activity at the tendon attachment site, and physically active people are more likely to exhibit presence of enthesophytes [2223]. Thus, presence of retrocalcaneal enthesophyte may imply that the patient has high activity level and is more liable to overuse injuries. In addition, retrocalcaneal enthesophytes are more common in patients with inflammatory diseases such as spondyloarthropathy as compared to healthy subjects [24252627]. Therefore, it could be possible that subjects with retrocalcaneal enthesophytes have systemic inflammatory diseases such as spondyloarthropathy despite our effort to exclude systemic inflammatory disease.

Presence of ‘pretreatment abnormal US echogenicity of Achilles tendon’ was found to be another positive parameter associated with immediate treatment success. In terms of standard conservative treatment, there are controversies regarding imaging studies (US or MRI) as a prognostic parameter. Bakkegaard et al. [12] have reported that US findings influence outcome of conservative treatment of chronic Achilles tendinopathy, in which pretreatment abnormal US findings (hyper- or hypo-echogenicity) were correlated with poor outcome after 6 months. In contrast, Khan et al. [17] revealed that US changes could not predict 12 months outcome of Achilles tendinopathy. To the best of our knowledge, present study is the first investigation on the association between the outcome of ESWT and US findings in Achilles tendinopathy. Further study on this issue involving large population and prospective study protocol are required.

In our study, the thickness of Achilles tendon was measured at its thickest point (37 feet on US and 8 on MRI). Contrary to our expectation that thickness of Achilles tendon would influence outcome of ESWT, it was intriguing to note that Achilles tendon thickness was not associated with immediate treatment success. This finding is similar to the results of former studies on plantar fasciitis, which stated that thickness of plantar fascia does not influence the outcome of ESWT [2829]. There have been conflicting results about association of Achilles tendon thickness with symptoms of patient. Some studies have suggested that Achilles tendon thickness is related to the level of pain and dysfunction, and improvement of discomfort is accompanied with reduction in tendon thickness [123031]. On the contrary, Kulig et al. [32] reported that there was no significant difference in thickness of Achilles tendon between asymptomatic and symptomatic dancers.

One major finding of our study, which attracted particular interest, was that, duration of ‘post-treatment soreness after first ESWT’ was the only one common factor influencing both immediate and long-term treatment success. In our study, all patients had at least half a day of soreness after receiving ESWT, which we defined as ‘post-treatment soreness’. Pain or tissue damage such as hematoma is a well-known side effect when using ESWT [3334]. Larger energy level seems more likely to be linked with greater pain and tissue damage. For example, capillary disruption and consecutive extravasation of erythrocytes after ESWT may introduce inflammatory reaction and ‘post-treatment soreness’ [3435]. In addition, sonographic and histological evaluation showed dose-dependent changes in the tendon and paratenon after ESWT ranging from transient swelling of the tendon with a minor inflammatory reaction to paratendinous fluid, marked histological changes with increased eosin staining, fibrinoid necrosis, fibrosis in the paratenon, and infiltration of inflammatory cells. [333435]. Thus, to some degree, ‘post-treatment soreness’ could be referred to as a result of appropriate biologic effect caused by appropriate delivery of therapeutic shockwave energy to the targeted area. On the other hand, excessive ‘post-treatment soreness’ could be a sign of tissue damage caused by over-delivered shockwave energy. Consequently, we authors suggest that duration of ‘post-treatment soreness’ have a feasibility of use as a parameter to determine appropriate delivery of shock energy.

In our study, a maximum of 12 sessions of ESWT (0.10–0.11 mJ/mm², 600 shocks, weekly) were conducted until RMS reached ‘good’ or ‘excellent’ (treatment success). Our ESWT protocol is the modified version of the protocol used in previous well-designed studies [493637]. In the reported studies, Furia et al. [437] performed just a single session of ESWT using high-energy (0.21 mJ/mm²) with 3,000 shocks; while Rompe et al. [36] executed 3 sessions of ESWT using low-energy (0.12 mJ/mm²) with 2,000 shocks per session. Total effective treatment energy is usually defined as energy flux density multiplied by number of shocks. In our protocol, although total effective treatment energy (maximum 720–792 mJ/mm²) was similar to those of previous studies (630 mJ/mm² in Furia et al. [437]; 720 mJ/mm² in Rompe et al. [36]), total effective treatment energy per each treatment session was much less (60–66 mJ/mm²) than the values reported by Furia et al. (630 mJ/mJ/mm²) and Rompe et al. (240 mJ/mm²).

We tried to avoid excessive delivery of energy to a targeted area per each treatment session. Therefore, to reach total effective treatment energy comparable to those of former studies, more treatment sessions (up to a maximum of 12 sessions) than former studies (one session in Furia et al.; three in Rompe et al.) were inevitably required.

Among 33 patients (45 feet) who met our eligibility criteria, 43 feet were available for long-term follow-up telephone interview and long-term follow-up rate was 96%. At both immediate follow-up (1 week after last ESWT) and long-term follow-up (mean 26 weeks after ESWT), significant decrease in subjective pain was noted, respectively (p<0.05). The immediate success rate of ESWT was 71.1% and long-term success rate was 90.3%. Although the outcome measures for clinical assessment were different, these results are similar to those published in previous randomized controlled trials, which reported ESWT as an effective method of treatment in chronic recalcitrant tendinopathy [93638]. Meanwhile, success rates in our study were found to be generally higher than previously reported studies [493637]. We believe that such results could be attributed to our efforts to reduce excessive ‘post-treatment soreness’ as follows: taking anti-inflammatory medication and applying ice massage before beginning of ESWT to reduce possible concomitant acute inflammatory pain; use of low-energy flux density (0.10–0.11 mJ/mm²) and less total effective treatment energy per each treatment session (60–66 mJ/mm²) to avoid excessive delivery of energy to a targeted area per each treatment session; and postponement of ESWT until the following week if ‘post-treatment soreness’ did not subside. Actually, the notion whether ESWT was successful or not at immediate follow-up was significantly associated with long-term success of ESWT in the present study.

There were some limitations in our study that should be discussed. Firstly, small number of subjects may have reduced statistical power of the results. Especially, at long-term follow-up, only four cases were included in the treatment failure group because most of the cases (39 feet of 43) turned out to be ‘treatment success’, which made investigation of the true factors that can affect long-term outcome of ESWT a difficult task. Secondly, retrospective data collection via chart review may have resulted in generation of incomplete information. Past medical history other than DM and anthropometric data, such as body mass index, could not be evaluated due to lack of medical records. Lastly, we could not consider activity level which is regarded as a contributor to Achilles tendinopathy [3940], since the afore-mentioned information were not available. Nevertheless, we believe that activity level had little impact on our results because all subjects were recommended to reduce their activity level for as long as possible and avoid impact activities. Further studies are needed to supplement these limitations.

In conclusion, low-energy ESWT appears to be an effective treatment option for chronic refractory Achilles tendinopathy while considering long-term follow-up. Immediate treatment success was associated with shorter mean duration of ‘post-treatment soreness’, shorter duration of ‘post-treatment soreness after first ESWT’, absence of retrocalcaneal enthesophyte on X-ray, and presence of pretreatment abnormal US echogenicity of AT. In case of long-term success, ‘post-treatment soreness after first ESWT’ was found to be the only positive prognostic parameter.